StudentShare
Contact Us
Sign In / Sign Up for FREE
Search
Go to advanced search...
Free

Drug Companys Restriction of Distribution of a Drug: A Genentech on Avastin Restriction - Case Study Example

Cite this document
Summary
This paper investigates the ethical and legal views of Genentech’s (Genetic Engineering Technology, Inc.) move in restricting Avastin’s distribution due to ophthalmologists’ use of the drug beyond its intended purpose in suppressing the growth of metastatic tumors through anti-angiogenesis. …
Download full paper File format: .doc, available for editing
GRAB THE BEST PAPER94.4% of users find it useful
Drug Companys Restriction of Distribution of a Drug: A Genentech on Avastin Restriction
Read Text Preview

Extract of sample "Drug Companys Restriction of Distribution of a Drug: A Genentech on Avastin Restriction"

Drug Company’s Restriction of Distribution of a Drug: A Case Study of Genentech on Avastin Restriction to Ophthalmologists on Eye Introduction This paper will investigate the ethical and legal views of Genentech’s (Genetic Engineering Technology, Inc.) move in restricting Avastin’s distribution due to ophthalmologists’ use of the drug beyond its intended purpose in suppressing the growth of metastatic tumors through anti-angiogenesis. An analysis will uncover the issues on Genentech’s apparent financial interest against the public interest in obtaining an efficient but more cost-effective alternative to Lucentis. Although there is success in revoking the previous decision of Genentech in disallowing physicians and pharmacists from obtaining Avastin from wholesale distributors1, there are still questions pertaining to the motives which need clarification. Why do they have to restrict the distribution of Avastin for off-label use? Why did they have to refuse the proposal of the American Ophthalmologist Community to conduct a comparative study between Avastin and Lucentis in AMD? What are their motives in doing this decision? We cannot hastily justify, so we are not yet certain whether they are just protecting their own financial interests, or there might be other reasons behind this decision which necessitates such action. Optical Usage of Avastin Even though the FDA approved the use of Avastin not for ophthalmic use, there is no issue of legality should physicians use the drug other than its recommended indication2, when the physician believe it to be appropriate, under his own risks of doing a medical malpractice3. Due to the drug’s anti-angiogenesis property, it was being used by physicians in treating various eye disorders precipitated by the leak caused by the blood vessels in the eye causing detachment of the retina4. The studies regarding the use of Avastin in eye disorders thru Pubmed search (limited to clinical trials and RCT and published within 3 years) reveals positive beneficial effects, yet requiring further long-term clinical studies. An attempt to investigate the long-term comparison between the two drugs was still on-going, yet an early result of the prospective randomized controlled trial reveals no difference between Avastin and Lucentis in effectiveness for choroidal neovascularizaton secondary to AMD5. Legal Issues Genentech’s decision to allow or suppress the availability of Avastin to the market may have legal implications that would threaten the company. The FDA approves the indication for the drugs after undergoing extensive research, toxicological assessments and clinical trials6. However, using the drugs beyond its indicated use, called ”off-label” use, is not illegal, only at the physician’s risk, depending on when he thinks of it to be appropriate. The drug is made for anti-cancer purposes but not for optical use intravitreously. There are barriers established by FDA for off-label use of drugs, yet not formal evaluation was established. The FDA prevents companies from advertising drugs beyond the indicated use, but will not prevent physicians to prescribe and administer the off-label use of the drug. Within three months, more than a thousand of AMD patients receive Avastin treatment, according to the Los Angeles Times7. It is not illegal for physicians to use the drug on ophthalmic use. However, it is uncertain whether Genentech will face any legal consequence should adverse effects occur for patients due to off-label use, other than the physician who administers it. Still, Genentech restricted the distribution of the drug even if it is not illegal for physicians to use it beyond the drug’s indication. What is known was that Avastin is not intended to be used intravitreously neither there were studies conducted by Genentech for this purpose. As long as Genentech does its “duty to warn”8, in informing the public of its possible danger when used beyond its indication, what legal consequences are they afraid of, if any? As cigarette manufacturers do their duty to warn by labelling “Government Warning: Cigarette Smoking is Dangerous to your Health” to their packaging, they will not face legal consequences should cigarette users manifest lung cancer, emphysema, and others. The same case in Avastin: placing as warning label on its packaging as “Not for Optical Use” will prevent them from undergoing legal consequences should ophthalmologists use the drug to the eye. Ethical Issues Although it has nothing to do with the ethical dimensions in treating study participants, the same ethics concepts can be applied to Genentech’s move. The ethical principles of beneficence and nonmaleficence9 shall be assessed regarding the decision made by Genentech to restrict Avastin distribution. Beneficence. Genentech is aware on the potential benefits of Avastin in the field of ophthalmology, and the researches done that suggest positive effects of the drug. It might be true that using the drug in an off-label purpose might be dangerous when used intravitreously (though no evidence so far), but the potential benefits outweigh the risks. Have they made an effort to reformulate Avastin for ophthalmology use? Can they just consider this drug to be just an alternative, if not the best, to the more expensive Lucentis? They are aware on how many patients with AMD would benefit from using the drug off-label, so this will be an issue that the decision does not consider the principle of beneficence. Nonmaleficence. If not for financial interests, perhaps Genentech’s concern would be the prevention of unnecessary risk or harm in using their product for off-label purpose. Their research of Avastin on optical application is not as extensive as what they did to Lucentis, so they are still uncertain if the drug is safe to use intravitreously. As an effort to minimize the dangers it may entail, Genentech made efforts to restrict the distribution of the drug to prevent the harm to patients due to its off-label use. They explained the risks involved in using the drug for optical purposes. However, should there be potential harm in using the product for optical use, what research have they made to test the safety and efficacy of Avastin administered intravitreously? If they can perform rigorous clinical trials for the more expensive Lucentis, why can’t they perform the same extensive research to the optical use of Avastin? Nonmalificence might be a factor, but not sufficient enough to justify their decision. Analysis The question remains about Genentech’s intents, if not to prevent legal consequences. Critics only see its financial intentions in restricting Avastin distribution, despite the company’s defence to this10. They are aware on how Avastin was be used by ophthalmologists as the mechanism of action between the two drugs are identical, only designed differently. If Avastin manifested positive effects in improving the condition of patients with AMD, why should they make a move to suppress it? Why do they refuse participating in comparative studies between Avastin an Lucentis in treating eye disorders11? The use of Avastin beyond its indication is not illegal and Genentech will not face legal repercussions should physicians decide to use it other than oncological purpose, yet they take action to restrict the distribution, if not totally phase it out from the market nor to disallow ophthalmologists to prescribe Avastin for ocular conditions. No wonder why many question their motives in doing so. If their concern is sincere, they won’t do anything to prevent the discovery of a less-costly alternative other than the more expensive product they are trying to market. Conclusion It is still uncertain whether Genentech’s motive was just to protect their financial interests in restricting Avastin distribution for ophthalmology or whether they are simply concerned about the risks due to non-intended use. The decision might be rooted from the principle of nonmaleficence in preventing unnecessary harm due to off-label use of the drug, but beneficence is ignored, knowing the potential benefit of the drug for optical use. This move was almost 3 years ago, and since the restriction was not successful, it is no longer necessary to conduct an in-depth case study as this won’t give much benefit than conducting a randomized clinical trial to compare the safety and effectiveness of the two drugs. More prospective, long-term, randomized clinical trials are recommended instead of putting too much emphasis on past issues which are already resolved. Read More
Cite this document
  • APA
  • MLA
  • CHICAGO
(Drug Companys Restriction of Distribution of a Drug: A Genentech on Case Study, n.d.)
Drug Companys Restriction of Distribution of a Drug: A Genentech on Case Study. Retrieved from https://studentshare.org/medical-science/1573033-genentechs-move-to-restrict-the-use-of-its-drug-avastin-its-cancer-drug-by-ophthalmologists-on-eye
(Drug Companys Restriction of Distribution of a Drug: A Genentech on Case Study)
Drug Companys Restriction of Distribution of a Drug: A Genentech on Case Study. https://studentshare.org/medical-science/1573033-genentechs-move-to-restrict-the-use-of-its-drug-avastin-its-cancer-drug-by-ophthalmologists-on-eye.
“Drug Companys Restriction of Distribution of a Drug: A Genentech on Case Study”, n.d. https://studentshare.org/medical-science/1573033-genentechs-move-to-restrict-the-use-of-its-drug-avastin-its-cancer-drug-by-ophthalmologists-on-eye.
  • Cited: 0 times

CHECK THESE SAMPLES OF Drug Companys Restriction of Distribution of a Drug: A Genentech on Avastin Restriction

Drug Companies Monopolies, Profits and Ethics

These types of restriction cause monopoly in the drug industry as few companies are controlling the sale of the drugs.... This article will explore the subject of drug companies monopolies, profit and ethics under the following divisions: patents make the monopoly in drug companies; drugs are available at lower prices in developing countries; prime profits of drug companies; ethics of drug companies.... Consumers expect too much from the drug industry....
5 Pages (1250 words) Essay

The Leadership Style

The leadership style at the genentech is that of a transformational leader.... genentech leaders endeavor to be leaders within their fields via their creative methodologies to scientific research, product development, commercialization and manufacturing (AAAS, 2013).... o fulfill genentech's mission as well as remain within the forefront of its industry, leaders at genentech continue to develop an atmosphere of full involvement, which allows the leaders to exploit the skills and knowledge of every employee....
5 Pages (1250 words) Essay

Drug Use, Regulation, and the Law

In reference to sequencing, research indicates that marijuana is one of the soft drugs that is narcotic and easily leads to a sequence in an individual who progresses on to associate the sequence of marijuana to another a drug for more pleasure.... One of the most significant examples of criticism on the law is when a drug agent stopped a woman known as Mendenhall at an airport claiming that she fitted the characteristics and behaviors of the drug-courier profile....
4 Pages (1000 words) Essay

General Elimination of Quantitative Restrictions

As the title suggests Article XI is concerned with the General Elimination of Quantitative restriction from Trade.... The following paper highlights that no prohibitions or restrictions other than duties, taxes or other charges, whether made effective through quotas, import or export licenses or other measures, shall be instituted or maintained by any contracting party on the importation of any product....
6 Pages (1500 words) Essay

The high cost of a breast cancer drug

The drug avastin has been in use in the treatment of some other forms of cancer, and has recently received FDA approval for its use in the treatment of breast cancer.... The annual cost involved in the use of avastin would be to the tune of $ 92,000.... Women with an annual family income would have to pay $ 55,000 for the avastin drug regimen for a year.... The use of avastin in the treatment of breast cancer virtually means an escalation in cost by as much as four times the other adjuvant drug treatments....
2 Pages (500 words) Essay

Drug illegalization

drug abuse which sometimes is commonly referred to as substance abuse it the consumption of a substance in this particular case (drug), in amounts or with methods that neither are approved nor supervised by any medical professional.... drug abuse is a serious public health problem that affects almost all communities in some way.... The use of drugs does not necessarily lead to abuse, neither is there a specific level at which drug use moves from casual to being problematic....
4 Pages (1000 words) Essay

Drug Development and Toxicology

hellip; Drug development is a gamble; one that involves spending billions of dollars and close to a decade before one can finally say that he has developed a drug that can actually cure a certain disease.... Before a drug enters the market, it must undergo different processes that confirm it is fit for use on the patients for whom its developers purposed.... When undergoing the approval process, such a drug will be disqualified from the clinics conducting the trials have no way of knowing the appropriate dosage....
4 Pages (1000 words) Essay

Netherlands National Drug Strategy

The paper "Netherlands National drug Strategy" highlights the Netherlands drug strategy is not sufficient in tackling the issue of illicit drugs among its population due to its liberal approach.... nbsp;… drug use problems became evident in many societies in the late 19th century through to the mid 20th century when slowly the use of many drugs transformed from acceptable application in medicinal procedures to illicit consumption under deviant environments....
10 Pages (2500 words) Essay
sponsored ads
We use cookies to create the best experience for you. Keep on browsing if you are OK with that, or find out how to manage cookies.
Contact Us